Dr. Chaudhary on History of CAR T-Cell Therapy

Preet M. Chaudhary, MD, PhD
Published: Wednesday, Jan 11, 2017



Preet M. Chaudhary, MD, PhD, chief of the Jane Anne Nohl Division of Hematology and Center for the Study of Blood Diseases, Department of Medicine, professor of Medicine, Ronald H. Bloom Family Chair in Lymphoma Research, and program director of the USC Norris Blood and Marrow Transplant Program, co-Leader of the Molecular Genetics Program, University of Southern California, discusses the history of chimeric antigen receptor (CAR) T-cell therapy.

Although there has been much excitement surrounding CAR T-cell therapy, the original design of the treatment has been around for more than 20 years. A group of investigators first began exploring CAR T cells in the early 1990s. The idea was a simple concept, he says, of taking the antigen-binding portion of an antibody and hooking it to a T-cell receptor in an effort to kill any antigen-expressing cancer cells.

However, at the time, many researchers were skeptical of this therapy because of its simplicity as well as the technical, logistical, regulatory, and manufacturing hurdles associated with it, he says.


Preet M. Chaudhary, MD, PhD, chief of the Jane Anne Nohl Division of Hematology and Center for the Study of Blood Diseases, Department of Medicine, professor of Medicine, Ronald H. Bloom Family Chair in Lymphoma Research, and program director of the USC Norris Blood and Marrow Transplant Program, co-Leader of the Molecular Genetics Program, University of Southern California, discusses the history of chimeric antigen receptor (CAR) T-cell therapy.

Although there has been much excitement surrounding CAR T-cell therapy, the original design of the treatment has been around for more than 20 years. A group of investigators first began exploring CAR T cells in the early 1990s. The idea was a simple concept, he says, of taking the antigen-binding portion of an antibody and hooking it to a T-cell receptor in an effort to kill any antigen-expressing cancer cells.

However, at the time, many researchers were skeptical of this therapy because of its simplicity as well as the technical, logistical, regulatory, and manufacturing hurdles associated with it, he says.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Expert Insights on the Management of Myeloproliferative Neoplasms: Evidence-based Approaches and Emerging Strategies to Address Challenges in CareSep 29, 20181.5
1st Annual LIVE Medical Crossfire®: Expert Exchanges in Hematologic Malignancies OnlineSep 30, 20188.0
Publication Bottom Border
Border Publication
x